iBio presentation highlights superior glycosylation for antibodies produced in plants
Data showing greater glycosylation homogeneity with the FastPharming system compared to traditional methods was presented at PEGS Boston 2022
8 May 2022
Blake Forman
Content Creator
iBio, Inc. a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, presented a poster at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Boston Conference & Expo, which took place May 2-6.
Rachel Jordan, Ph.D., a senior product manager at iBio, presented the poster, titled "Plant-Made Antibodies Show Superior Glycosylation Homogeneity While Retaining Pharmacokinetic Properties," which highlighted:
- The production of a single uniform G0 glycosylation pattern, lacking fucose and xylose, of NISTmAb and rituximab when compared to Chinese Hamster Ovary (CHO) cell culture produced antibodies, which contain more heterogeneous glycosylation patterns.
- Comparability of in vivo rodent pharmacokinetic profiles for NISTmAb and rituximab produced using mammalian cell culture and the FastPharming System.
- How rapid, scalable transient expression in plants of high-quality mAbs for in vivo studies can significantly shorten the time to achieve in vivo proof-of-concept.